Do SGLT2 inhibitors improve cardiovascular outcomes and mortality in patients with heart failure?
SGLT2 inhibitors significantly reduce cardiovascular and all-cause mortality in patients with heart failure without increasing serious adverse events.
SGLT2 inhibitors significantly improve cardiovascular outcomes including cardiovascular and all-cause mortality in patients with HF without an increased risk of serious adverse events. A trend towards benefit was observed in patients with HF with preserved ejection fraction.
Butler et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: